onc Videos

Videos

Helene Blons, PhD, PharmD, Georges Pompidou Hospital

Videos

Impact of BRCA1 and RAD15 Methylation on Maintenance Olaparib Plus Bevacizumab Efficacy in Ovarian Cancer

06/16/2023

At the 2023 ASCO Annual Meeting, Helene Blons, PhD, PharmD, discusses results from an abstract addressing the impact of BRCA1 and RAD51 methylation on the efficacy of olaparib plus bevacizumab maintenance treatment, from the...

At the 2023 ASCO Annual Meeting,...

06/16/2023

Oncology

Daniel Gomez, MD, Memorial Sloan Kettering

Videos

The Case Against Prophylactic Cranial Irradiation for Patients With SCLC

06/15/2023

Daniel Gomez, MD, summarizes his argument against prophylactic cranial irradiation for patients with small-cell lung cancer, a stance he defended in a debate session at the Great Debates and Updates in Lung Cancer conference in Chicago,...

Daniel Gomez, MD, summarizes his...

06/15/2023

Oncology

Corey Langer, MD, Abramson Cancer Center

Videos

How to Handle Elderly Patients and Individuals With Performance Status 2 and NSCLC

06/14/2023

At the 2023 Great Debates and Updates in Lung Cancer in Chicago, Illinois, Corey Langer, MD, Abramson Cancer Center, University of Pennsylvania, discussed how to best care for the elderly patient population, as well and patients with...

At the 2023 Great Debates and...

06/14/2023

Oncology

Videos

Fractionated Busulfan Treatment Reduced Toxicities Among Patients With AML and MDS

06/14/2023

Uday Popat , MD;

Uday Popat, MD, presented data from a clinical trial that indicated the fractionation of busulfan reduced toxicities among patients with AML and MDS. This data was presented at the 2023 ASCO annual meeting.

Uday Popat, MD, presented data...

06/14/2023

Oncology

Videos

Evaluating BCL6-Positive and CD10-Positive Expression for Mantle Cell Lymphoma Treatment and Management

06/14/2023

Won Jin Jeon , MD;

At the 2023 ASCO annual meeting, Won Jin Jeon, MD, presented data from a meta-analysis that explored the prognostic value of identifying BCL6 and CD10 variants in the treatment and management of mantle cell lymphoma.

At the 2023 ASCO annual meeting,...

06/14/2023

Oncology

Lars Henrik Jensen, MD, University Hospital of Southern Denmark

Videos

Neoadjuvant Chemotherapy for Locally Advanced Colorectal Cancer

06/14/2023

On site at ASCO 2023, Dr Lars Henrik Jensen shares results from the phase 3 NeoCol trial evaluating the addition of neoadjuvant chemotherapy to initial surgery for patients with locally advanced colon cancer.

On site at ASCO 2023, Dr Lars...

06/14/2023

Oncology

Videos

MonumenTAL-1 Study Identifies Impressive Responses to Talquetamab Among Patients With Heavily Pretreated R/R MM

06/13/2023

Carolina Schinke , MD;

At the 2023 ASCO annual meeting, Carolina Schinke, MD, discussed updated results from the MonumenTAL-1 trial which indicated that patients with heavily pretreated R/R multiple myeloma had impressive responses to treatment with talquetamab.

At the 2023 ASCO annual meeting,...

06/13/2023

Oncology

Videos

Glofitamab Monotherapy for Patients With R/R Diffuse Large B-Cell Lymphoma

06/13/2023

Lorenzo Falchi, MD presents extended follow-up from a pivotal phase 2 study on CD20-CD3 bispecific antibody glofitamab monotherapy for patients with R/R DLBCL.

Lorenzo Falchi, MD presents...

06/13/2023

Oncology

Michael Castro, MD, Beverly Hills Cancer Center

Videos

Effect of Proton Pump Inhibitor Use on Glioblastoma Survival Outcomes

06/13/2023

Michael Castro, MD, discusses the results of a retrospective study evaluating the effect proton pump inhibition use may have on survival outcomes of patients with glioblastoma.

Michael Castro, MD, discusses...

06/13/2023

Oncology

Videos

Teclistamab Demonstrates Safety, Efficacy for Patients With R/R Multiple Myeloma

06/12/2023

Niels W.C.J. van de Donk, MD, PhD, presents 2-year follow-up results from the MajesTEC-1 trial, which indicated that teclistamab demonstrated safety and efficacy among heavily pre-treated patients with R/R multiple myeloma.

Niels W.C.J. van de Donk, MD,...

06/12/2023

Oncology

Recent News

News

Tumor Mutational Status May Predict Recurrence, Survival Patterns for Patients With Early-Stage Non-Small Cell Lung Cancer

11/18/2024

Stephanie Holland ;

According to results from a retrospective analysis, tumor mutational status can potentially predict recurrence and survival patterns for patients with surgically resected, stage I non-small cell lung cancer.

According to results from a...

11/18/2024

Oncology

News

FDA Grants Approval to Revumenib for Patients With R/R Acute Leukemia With KMT2A Translocation

11/17/2024

On November 15, 2024, the FDA approved menin inhibitor revumenib for adult and pediatric patients 1 year and older with relapsed/refractory acute leukemia with KMT2A translocation.

On November 15, 2024, the FDA...

11/17/2024

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology